The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity
Open accessAbstract
Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Pham, C. G., Bubici, C., Zazzeroni, F., Papa, S., Jones, J., Alvarez, K., Jayawardena, S., De Smaele, E., Cong, R., Beaumont, C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.017 · Cited by 663
Turkseven, S., Kruger, A., Mingone, C. J., Kaminski, P., Inaba, M., Rodella, L. F., Ikehara, S., Wolin, M. S., & Abraham, N. G. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2005 · Cited by 256 · cited 1×
“This enzyme was recently shown to mediate upregulation of SOD (Frankel et al., 2000; Turkseven et al., 2005), which seems to play a protective role against PDT-induced cell death (Golab et al., 2003; Dolgachev et al., 2005).”
Background
Cited by
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
“Targeting enzymes participating in ROS scavenging (such as superoxide dismutase, HO-1, or nitric oxide synthase) with selective inhibitors has been shown to improve the antitumor activity of PDT.(41,124,127) Antivascular effects of PDT can be further potentiated by cyclooxygenase (COX) inhibitors,(110) antiangiogenic…”
BackgroundSelf-citationPhotodynamic therapy and anti-tumour immunity
Castano, A. P., Mroz, P., & Hamblin, M. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1894 · Cited by 2,676
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
“Moreover, HO-1 expression in tumor cells can be further increased by anticancer treatments (chemo-, radio-, and photodynamic therapy) [90], and it has been hypothesized that HO-1 and its products may have an important role in the development of a resistant phenotype.”
BackgroundNrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
LAU, A., VILLENEUVE, N., SUN, Z., WONG, P., & ZHANG, D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.003 · Cited by 645
Photodynamic therapy (PDT) of cancer: from local to systemic treatment
Dabrowski, J. M., & Arnaut, L. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00132c · Cited by 501
Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity
Donohoe, C., Senge, M. O., Arnaut, L. G., & Gomes-da-Silva, L. C. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.07.003 · Cited by 442
Heme Oxygenase-1 in Tumors: Is It a False Friend?
Jozkowicz, A., Was, H., & Dulak, J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1659 · Cited by 382
Self-citationMechanisms of Resistance to Photodynamic Therapy
Casas, A., Di Venosa, G., Hasan, T., & Batlle, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795843272 · Cited by 322
Heme Oxygenase-1 and Carbon Monoxide in Vascular Pathobiology: Focus on Angiogenesis
Dulak, J., Deshane, J., Jozkowicz, A., & Agarwal, A. (2008) · Circulation · doi:10.1161/circulationaha.107.698316 · Cited by 304
Self-citationThe Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1958174 · Cited by 295
ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis
Dey, S., Sayers, C. M., Verginadis, I. I., Lehman, S. L., Cheng, Y., Cerniglia, G. J., Tuttle, S. W., Feldman, M. D., Zhang, P. J. L., Fuchs, S. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78031 · Cited by 282
Heme Oxygenase-1 and the Vascular Bed: From Molecular Mechanisms to Therapeutic Opportunities
Loboda, A., Jazwa, A., Grochot-Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., Jozkowicz, A., & Dulak, J. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2043 · Cited by 265
Self-citationHeme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Self-citationBroekgaarden, M., Weijer, R., van Gulik, T. M., Hamblin, M. R., & Heger, M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9588-7 · Cited by 255
Miyake, M., Ishii, M., Kawashima, K., Kodama, T., Sugano, K., Fujimoto, K., & Hirao, Y. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00543.x · Cited by 79
Approaches to improve photodynamic therapy of cancer
Firczuk, M. (2011) · Frontiers in Bioscience · doi:10.2741/3684 · Cited by 55
“PDT has been shown to increase HO-1 expression at both mRNA and protein levels (58-59).”
BackgroundAnayo, L., Magnussen, A., Perry, A., Wood, M., & Curnow, A. (2018) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22809 · Cited by 19
“5 generated, overwhelm the cell’s inherent antioxidant defense and ultimately lead to cell death via apoptosis and necrosis, or alternatively, a destructive form of autophagy [18-25].”
Background
Metadata
- Authors
- Nowis, D., Legat, M., Grzela, T., Niderla, J., Wilczek, E., Wilczynski, G. M., Głodkowska, E., Mrówka, P., Issat, T., Dulak, J., Józkowicz, A., Waś, H., Adamek, M., Wrzosek, A., Nazarewski, S., Makowski, M., Stokłosa, T., Jakóbisiak, M., & Gołab, J.
- Venue
- Oncogene
- Published
- 2006-02-06
- Volume
- 25
- Issue
- 24
- Pages
- 3365-3374
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2025541083
- Cited by
- 184
- References
- 3
- FWCI
- 11.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.